Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 8/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MET | P08581 | 2/20 | 0.40 |
| ▸ | MST1R | Q04912 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | BRD4 | O60885 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | KIF11 | P52732 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8902362 | 0.76 | EGFR (0.45) | MEN1KMT2AMAPTPOLB | |
| SCHEMBL4110021 | 0.75 | BRD4 (0.44) | HPGDMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL4110274 | 0.74 | KDM4E (0.51) | HPGDMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL3415258 | 0.73 | BRD4 (0.42) | HPGDMETMST1RMAPTSMN1; SMN2 | |
| SCHEMBL3412817 | 0.73 | SMN1; SMN2 (0.42) | HPGDMAPTSMN1; SMN2HSD17B10BRD4 | |
| SCHEMBL8902031 | 0.72 | MAPT (0.37) | HPGDMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL4115657 | 0.71 | MAPT (0.38) | HPGDMEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL4110377 | 0.71 | MAPT (0.39) | HPGDMEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL8900141 | 0.70 | KDM4E (0.44) | MEN1KMT2AMAPTSMN1; SMN2POLB | |
| SCHEMBL8900693 | 0.70 | HTR3A (0.42) | MEN1KMT2AALDH1A1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188284-B2 | 2-aminoquinolines | HOFFMAN-LA ROCHE INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-20090227583-A1 | 2-AMINOQUINOLINES | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227583-A1 | 2-AMINOQUINOLINES | HTR5A, HTR2C, HTR2B | HPGD 2590/4885MEN1 3687/4885KMT2A 1042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.